← Every applicant
Strides Pharma FDA Approvals
27 new drug approvals and 0 device clearances on file. This applicant is not matched to a listed company.
Newest first
A new drug approval is an original application; a 510(k) is a device shown equivalent to one already sold.
| Product |
|---|
| MILNACIPRAN HYDROCHLORIDENew drugSep 15, 2026TABLET, ORAL |
| CELECOXIBNew drugApr 29, 2025CAPSULE, ORAL |
| ACETAMINOPHEN AND IBUPROFENNew drugJan 17, 2025TABLET, ORAL |
| FLUOXETINE HYDROCHLORIDENew drugSep 13, 2024TABLET, ORAL |
| THEOPHYLLINENew drugSep 5, 2024TABLET, EXTENDED RELEASE, ORAL |
| SUCRALFATENew drugMay 21, 2024SUSPENSION, ORAL |
| SEVELAMER CARBONATENew drugMay 9, 2024TABLET, ORAL |
| FLUOXETINE HYDROCHLORIDENew drugApr 5, 2024TABLET, ORAL |
| GABAPENTINNew drugMar 4, 2024TABLET, ORAL |
| PREGABALINNew drugJan 24, 2024CAPSULE, ORAL |
| ATORVASTATIN CALCIUMNew drugDec 21, 2023TABLET, ORAL |
| LEVETIRACETAMNew drugNov 20, 2023SOLUTION, ORAL |
| PREGABALINNew drugApr 26, 2023CAPSULE, ORAL |
| POTASSIUM CHLORIDENew drugNov 17, 2022SOLUTION, ORAL |
| AZITHROMYCINNew drugJul 15, 2022TABLET, ORAL |
| AZITHROMYCINNew drugJul 12, 2022TABLET, ORAL |
| IBUPROFENNew drugJun 9, 2022SUSPENSION/DROPS, ORAL |
| IBUPROFENNew drugMay 27, 2022SUSPENSION, ORAL |
| COLCHICINENew drugMar 10, 2022TABLET, ORAL |
| OSELTAMIVIR PHOSPHATENew drugJan 13, 2022FOR SUSPENSION, ORAL |
| EFAVIRENZNew drugJun 16, 2021TABLET, ORAL |
| POTASSIUM CHLORIDENew drugMar 11, 2021FOR SOLUTION, ORAL |
| IBUPROFENNew drugFeb 22, 2021SUSPENSION, ORAL |
| ATOMOXETINE HYDROCHLORIDENew drugFeb 18, 2021CAPSULE, ORAL |
| PREDNISONENew drugFeb 11, 2021TABLET, ORAL |
| URSODIOLNew drugJan 22, 2021CAPSULE, ORAL |
| EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATENew drugJan 13, 2021TABLET, ORAL |